FREE COVID-19
Support Package

for Choice Aged Care Clients

covid19 aged care resources

How We Can Help

PVP-I Intra-Nasal Sprays

Lockdown Kit containing specially compounded Povidone-iodine (PVP-I) intra-nasal sprays for each frontline care worker.

CHRIS

Virtual Pharmacist CHRIS provision (an industry first telehealth system supporting remote clinical care).

Microbe Surface Testing

Environment microbe surface testing to confirm effective infection control practices, benchmarked via the PPASS-3 Tool.

Intervention Services

A suite of proactive clinical pharmacy intervention services for consumers at high risk of COVID-19 mortality

FREE access to the leading aged care benchmarking platform

ppass logo
Psychotropic, Polypharmacy & Antimicrobial Support for Standard 3 Tool.

PPASS-3 Tool Features:

Why PPASS-3 has become the industry's leading benchmarking tool

COVID Aged Care Support

PVP-I instra-nasal spray information

SARS-CoV-2, the virus that causes COVID19, is thought to be transmitted through respiratory droplets, airborne transmission and physical contact from contaminated surfaces to the nose and mouth. There appears to be a large amount of virus in the nasal and throat area and it is thought that infection from these areas might to spread to the lower airway causing lung disease.

COVID Aged Care resources

What is PVP-I?

Povidone-iodine (PVP-I) is an antiseptic that has been used for the prevention or management of wound infections for over 150 years. Its antibacterial, antiviral, and antifungal properties and its safety have been well-documented. It has been previously used in intranasal preparations against MRSA infection as well as in oral preparations in laboratory studies of other viruses such as SARS-CoV, MERS-CoV, H1N1, and rotavirus with good efficacy. Clinical trials are currently underway to assess the potential use of Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel. It is thought that the use of povidone iodine nasal spray may act to decontaminate the nasal area and reduce transmission of SARS-CoV-2.

Microbe Surface Testing

What are the benefits

This is the only evidence based method to confirm to stakeholders (Board members through to consumers) that the facility’s environment related infection control or outbreak management procedures are effective.

The service identifies opportunities for continuous improvement in environmental cleaning and hand hygiene practices.

Exhibits high-level compliance to Quality Framework Requirements Standard 3 (3)(g); Standard 5 (3)(b); and Standard 8 (3)(e).

A proactive service that categorically helps protect residents and staff from infection, minimising health complications & staffing disruptions.

What's involved?

1) Our Clinical Pharmacist visits your facility and conducts agar dip-slide swabs (6 randomised test sites are completed out of 30 established benchmarked objects & surfaces).

2) The samples are placed into Choice Aged Care’s nearest incubator (Brisbane, Sydney or Melbourne).

3) Total Microbe Count is analysed 24 hours later, benchmarked via the PPASS-3 Tool and results with recommendations are submitted to management.

Enter system password for access:

Patient/Consumer Consent Form for Choice Aged Care Services

I, or my authorised representative, understand and consent to the provision of the following services (where indicated and/or referred for):

Medicine Review (Home or Residential) service

Nurse Practitioner (NP) service

Geriatrician service

Risks and Benefits: I have had the opportunity to ask questions about treatment, risks, benefits, and alternatives. Any questions have been answered to my satisfaction. I understand that all treatments, including telehealth, have potential risks and benefits. Specific risks include limitations on physical examination and potential technology issues. Benefits include increased access to care and convenience.

Confidentiality: My personal health information will be kept confidential according to the law and Choice Aged Care’s privacy policy. This policy can be accessed at: https://www.choiceagedcare.com.au/wp-content/uploads/2024/05/CAC-Privacy-and-Confidentiality-Policy.pdf

  1. If referred for, I consent to receive the HMR Service and to the collection of my personal information by the Pharmacy Programs Administrator and the Australian Government Department of Health and Aged Care to enable the pharmacy to claim a payment for delivery of that service and for program monitoring and evaluation purposes.
  2. Consent for Nurse Practitioner Telehealth Services:
    I consent to the proposed treatment or procedure, including telehealth services, conducted securely to protect my privacy.
  3. Consent for Case Conferencing:
    I consent to members of the Care Choice Services Team attending case conferences if required for my care.
  4. Consent for Representation in Limited Circumstances:
    I consent for an authorised person to act on my behalf if I am unable to participate fully. By indicating consent has been obtained, I acknowledge that I have read and understood the information provided above and consent to the proposed services. If you are indicating consent is provided on behalf of the intended service recipient, please indicate your relationship to the patient in the comments field provided e.g. Parent or guardian of child Enduring Guardian (recognised by a relevant state or territory law), Enduring Power of Attorney, (recognised by a relevant state or territory law), A person who has been nominated in writing by the patient while the patient was capable of giving consent, A person recognised by a relevant state or territory law.